Abstract
Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 1503-1515 |
| Number of pages | 13 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 20 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Cytotoxic Chemotherapy
- liposarcoma
- myxoid/round cell
- pleomorphic
- targeted therapy
- well-/dedifferentiated
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Pharmacotherapy for liposarcoma : current state of the art and emerging systemic treatments. / Suarez-Kelly, Lorena P.; Baldi, Giacomo G.; Gronchi, Alessandro.
In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 12, 01.01.2019, p. 1503-1515.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacotherapy for liposarcoma
T2 - current state of the art and emerging systemic treatments
AU - Suarez-Kelly, Lorena P.
AU - Baldi, Giacomo G.
AU - Gronchi, Alessandro
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.
AB - Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management. Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma. Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.
KW - Cytotoxic Chemotherapy
KW - liposarcoma
KW - myxoid/round cell
KW - pleomorphic
KW - targeted therapy
KW - well-/dedifferentiated
UR - http://www.scopus.com/inward/record.url?scp=85071651328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071651328&partnerID=8YFLogxK
U2 - 10.1080/14656566.2019.1618271
DO - 10.1080/14656566.2019.1618271
M3 - Review article
C2 - 31136210
AN - SCOPUS:85071651328
VL - 20
SP - 1503
EP - 1515
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 12
ER -